Related Experiment Video
Updated: Jul 2, 2026
07:36
Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG (hOMING)
Published on: March 14, 2019
Validation of the SoloSTAR insulin pen
Sherwyn Schwartz1, Aleksandra Vlajnic
1Diabetes and Glandular Disease Research Associates, San Antonio, Texas 78229-4801, USA. slschwartz@dgdclinic.com
Diabetes Technology & Therapeutics
|August 22, 2008
Summary
The SoloSTAR insulin pen is effective for patients with type 1 or type 2 diabetes, demonstrating high success rates in dose delivery with or without face-to-face training. This new pen is accurate and precise for diabetes management.
Area of Science:
- Diabetes management
- Medical device validation
- Pharmacology
Background:
- A new disposable insulin pen, SoloSTAR, was developed for insulin glargine delivery.
- The study aimed to validate its usability for patients with type 1 or type 2 diabetes.
Purpose of the Study:
- To assess the efficacy and usability of the SoloSTAR pen for insulin glargine administration.
- To evaluate dose accuracy and precision in a real-world setting.
Main Methods:
- A single-center, open-label trial involving patients with type 1 or type 2 diabetes.
- Subjects received either face-to-face or self-training before performing three dose-delivery repetitions.
- Pen accuracy and precision were evaluated by weighing pens before and after dose delivery.
Main Results:
- High success rates in dose delivery were observed: 100% in the face-to-face training group and 98% in the self-training group.
- Mean delivered doses were accurate, with most repetitions falling within a narrow range (38-42 units).
- Successful completion of safety tests varied between training groups.
Conclusions:
- The SoloSTAR pen is validated for use in patients with diabetes, regardless of training method.
- The device demonstrated ease of use, accuracy, and precision in delivering insulin glargine.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:05Insulin Secretory Vesicles
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
01:17Solenoids
A solenoid is a conducting wire coated with an insulating material, wound tightly in the form of a helical coil. The magnetic field for a solenoid is the vector sum of the magnetic field due to its individual turns. For an ideal solenoid, the magnetic field inside is almost uniform and parallel to the solenoid axis, while the magnetic field outside the solenoid is nearly zero.
Each turn in a solenoid can be approximated as a circular current carrying coil that generates a dipole moment. The...
Each turn in a solenoid can be approximated as a circular current carrying coil that generates a dipole moment. The...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...